Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 34Carcinoma, Non-Small-Cell Lung 20Squamous Cell Carcinoma of Head and Neck 19Esophageal Neoplasms 19Head and Neck Neoplasms 13Nasopharyngeal Carcinoma 12Uterine Cervical Neoplasms 11Pancreatic Neoplasms 9Oropharyngeal Neoplasms 8Lung Neoplasms 7Glioblastoma 6Esophageal Squamous Cell Carcinoma 6Carcinoma, Squamous Cell 6Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Mouth Neoplasms 4Hypopharyngeal Neoplasms 4Colorectal Neoplasms 4Carcinoma 4Adenocarcinoma 4Radiation Injuries 3Pathologic Complete Response 3Laryngeal Neoplasms 3Breast Neoplasms 3Thymoma 2Resectable Esophageal Cancer 2Neoplasms by Site 2Nasopharyngeal Neoplasms 2NSCLC 2

Interventions

Gemcitabine 4Leucovorin 2Fluorouracil 2tremelimumab 1pamrevlumab 1irinotecan sucrosofate 1folfirinox 1durvalumab 1Taxes 1Specimen Handling 1Radiosurgery 1Oxaliplatin 1Medical Marijuana 1Irinotecan 1Heavy Ion Radiotherapy 1Chemoradiotherapy 1Capecitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Cancer Non-resectable × Chemoradiotherapy × Clear all
NCT07386704 2026-02-04

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

Peking University First Hospital

Phase 2 Enrolling by invitation
30 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡